120 related articles for article (PubMed ID: 1732631)
1. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.
Neubauer BL; Merriman RL; Best KL; Goode RL; Sarosdy MF; Tanzer LR; Howbert JJ
J Urol; 1992 Feb; 147(2):500-4. PubMed ID: 1732631
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Neubauer BL; Best KL; Counts DF; Goode RL; Hoover DM; Jones CD; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Prostate; 1995 Oct; 27(4):220-9. PubMed ID: 7479389
[TBL] [Abstract][Full Text] [Related]
3. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
[TBL] [Abstract][Full Text] [Related]
4. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
[TBL] [Abstract][Full Text] [Related]
5. Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Merriman RL; Smith GF; Tanzer LR; Hoover DM
Prostate; 1986; 8(3):265-76. PubMed ID: 3703746
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Hoover DM; Smith GF; Tanzer LR; Merriman RL
J Urol; 1986 Jan; 135(1):163-6. PubMed ID: 3941458
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
Sarosdy MF; Higdon AL; Demoor CA
J Urol; 1996 Jun; 155(6):2085-9. PubMed ID: 8618341
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
[TBL] [Abstract][Full Text] [Related]
10. Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.
Cadieux PA; Mikolajczak SA; Reeves J; Strathdee C; Reid G; Panchal CJ; Clarke MW
Cancer Invest; 2006; 24(3):246-55. PubMed ID: 16809150
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
Oades GM; Dredge K; Kirby RS; Colston KW
BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
13. A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients.
Morré DJ; Reust T
J Bioenerg Biomembr; 1997 Jun; 29(3):281-9. PubMed ID: 9298713
[TBL] [Abstract][Full Text] [Related]
14. The antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes.
Morré DJ; Wu LY; Morré DM
Biochim Biophys Acta; 1995 Nov; 1240(1):11-7. PubMed ID: 7495842
[TBL] [Abstract][Full Text] [Related]
15. Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methylphenylsulfonyl)-N'-(4-cholorophenyl) urea (LY181984).
Sun E; Lawrence J; Morré DM; Sun I; Crane FL; MacKellar WC; Morré DJ
Biochem Pharmacol; 1995 Oct; 50(9):1461-8. PubMed ID: 7503797
[TBL] [Abstract][Full Text] [Related]
16. Effect of dimethylsulfoxide on the proliferation and glycosaminoglycan synthesis of rat prostate adenocarcinoma cells (PAIII) in vitro: isolation and characterization of DMSO-resistant cells.
Kaneski CR; Constantopoulos G; Brady RO
Prostate; 1991; 18(1):47-58. PubMed ID: 1987579
[TBL] [Abstract][Full Text] [Related]
17. Oral bropirimine immunotherapy of rodent prostate cancer.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():5-9. PubMed ID: 9076480
[TBL] [Abstract][Full Text] [Related]
18. NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) at an external site.
Morré DJ
Biochim Biophys Acta; 1995 Dec; 1240(2):201-8. PubMed ID: 8541291
[TBL] [Abstract][Full Text] [Related]
19. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer.
Naik HR; Lehr JE; Pienta KJ
Anticancer Res; 1994; 14(6B):2617-9. PubMed ID: 7872690
[TBL] [Abstract][Full Text] [Related]
20. Response of a cell-surface NADH oxidase to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenylurea) (LY181984) modulated by redox.
Morré DJ; Wu LY; Morré DM
Biochim Biophys Acta; 1998 Mar; 1369(2):185-92. PubMed ID: 9518604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
